INCR Intercure Ltd. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1857030 · Reporting currency ILS · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: ILS | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 238.84M | 355.55M |
| Cost of revenue | 203.25M | 247.21M |
| Gross profit | 30.23M | 105.09M |
| R&D expense | 414,000 | 388,000 |
| SG&A expense | 53.67M | 42.61M |
| Operating income | -67.21M | -41.57M |
| Pretax income | -87.32M | -61.28M |
| Income tax | -14.53M | 2.25M |
| Net income | -67.80M | -61.96M |
| EBITDA | -51.84M | -28.40M |
| EPS (basic) | -1.48 | -1.36 |
| EPS (diluted) | -1.48 | -1.36 |
| Balance sheet | ||
| Cash & equivalents | 78.32M | 101.14M |
| Short-term investments | 333,000 | 187,000 |
| Receivables | 51.85M | 60.41M |
| Inventory | 120.31M | 105.47M |
| Current assets | 391.80M | 418.80M |
| PP&E, netmay include right-of-use assets (IFRS) | 105.24M | 97.47M |
| Goodwill | 224.59M | 221.08M |
| Total assets | 762.57M | 786.61M |
| Current liabilities | 226.75M | 225.87M |
| Short-term debt | 69.44M | 88.19M |
| Long-term debt | 113.98M | 82.20M |
| Total debt | 183.41M | 170.40M |
| Total liabilities | 364.90M | 329.55M |
| Shareholders' equity | 396.97M | 455.11M |
| Net debt | 105.10M | 69.26M |
| Cash flow statement | ||
| Operating cash flow | -66.93M | -53.63M |
| Capital expenditure | 4.38M | 2.62M |
| Free cash flow | -71.30M | -56.25M |
| Investing cash flow | 17.69M | 4.77M |
| Financing cash flow | 26.45M | -82.89M |
| Depreciation & amortization | 15.37M | 13.17M |
| Stock-based compensation | 2.28M | 2.59M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, ILS, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.